1. Louise J. Robertson et al. IgG antibody production and persistence to 6 months following SARS-CoV-2 vaccination: a Northern Ireland observational study, Vaccine, 2022, ISSN 0264-410X, https://doi.org/10.1016/j.vaccine.2022.02.087.
    2. Letko M et al. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nature Microbiology. 2020 April;5(4):562-9.
    3. Long QX et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nature Medicine, June 2020;26(6):845-848.
    4. Crawford K et al. Dynamics of neutralising antibody titres in the months after SARS-CoV-2, Journal Infectious Diseases. 2020 September; 223 (2) 197-205
    5. Seow J et al. Longitudinal observation and decline of neutralizing antibody responses, Nat Microbiol. 2020 December; 5:1598-1607
    6. Post N, et al. Antibody response to SARSCoV-2 infection in humans: A systematic review. PLoS One. 2020;15(12): e0244126.
    7. Andrews, K et al. Heterogeneous antibodies against SARS-CoV-2 spike RBD and nucleocapsid. JCI Insight. 2020 September; 17:5(18):e142386.
    8. Dispinseri, S et al. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nat Communications. May 2021; 12: 2670
    9. Premkumar L, et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Science Immunology June 2020; 5 (48).
    10. Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine. July 2021; 27: 1205–1211.
    11. Naaber, P. et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study Lancet Regional Health Europe. November 2021; 10; 100208
    12. Thomas, S. J. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. New England Journal of Medicine. November 2021; 385: 1762-1773.
    13. Walker et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nature Microbiology. July 2021; 6(9):1140–1149.
    14. Tom Tipton et al. T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. Lancet November 2021. DOI:https://doi.org/10.1016/S2666-5247(21)00275-5
    15. Munro C, Covid-19: 40% of patients with weakened immune system mount lower response to vaccines. British Medical Journal. August 2021;374:n2098
    16. Yamayoshi et al. Antibody titres against SARS-CoV-2 decline, but do not disappear for several months. E Clinical Medicine February 2021;32:100734
    1. https://www.timesofisrael.com/israeli-research-finds-covid-19-antibody-levels-differ-between-men-and-women/
    2. WHO Director-General’s opening remarks at the media briefing on COVID-19 – 11 March 2020
    3. “UK medicines regulator gives approval for first UK COVID-19 vaccine”. Medicines and Healthcare Products Regulatory Agency, Government of the UK. 2 December 2020.
    4. “Coronavirus (COVID-19) Vaccinations – Statistics and Research”. Our World in Data. Retrieved 11 December 2021
    1. Freedom Fails as COVID cases surge amidst new variant (ZOE Study) 21st Oct 2021: https://www.youtube.com/watch?v=sJlD3R8QDd4
    2. How to use the AbC-19 COVID-19 rapid antibody test: https://www.youtube.com/watch?v=WqT2z8jCEHs
    3. Antibody test instead of vaccine? Ky. lawmaker files resolution to recognize status: https://www.youtube.com/watch?v=hOeWxqpJWaE

KNOW YOUR COVID-19 ANTIBODY STATUS - EVERYBODY IS DIFFERENT

  • AbC-19 Semi-Q

    Semi-Quantitative COVID-19 IgG Antibody Test

    Reliably monitor an individual’s COVID-19 antibody status. Remove the guesswork around immune response and antibody waning.

    Learn more
  • AbC-19

    COVID-19 IgG Antibody Test

    Reliably screen for the presence or absence of COVID-19 IgG antibodies. Remove the guesswork around confirming immune responses.

    Learn more